Finance
Pfizer GLP-1 Weight Loss Drug Available for Pre-Order in China
Published by Global Banking & Finance Review®
Posted on April 22, 2026
2 min readLast updated: April 22, 2026
Add as preferred source on GoogleQuick Summary
Pfizer’s GLP‑1 drug Xianweiying (ecnoglutide) is now available for pre‑order in China via JD.com at 489 yuan, with shipping starting April 27, intensifying competition in China’s fast‑growing, multibillion‑yuan weight‑loss drug market.
Pfizer Launches GLP-1 Weight Loss Drug Xianweiying for Pre-order in China
Pfizer’s Entry into China’s Weight Loss Drug Market
By Andrew Silver
Pre-order Availability and Pricing Details
SHANGHAI, April 22 (Reuters) - Pfizer’s GLP-1 weight management treatment Xianweiying is available for pre-order in China, a Reuters check on a local e-commerce platform showed, ramping up competition with rivals in a market analysts expect to be worth billions of dollars.
A spokesperson for Pfizer did not immediately respond to a request for comment.
Product Pricing and Shipping Information
A 1.2 ml Xianweiying injector pen with shipping beginning on April 27 costs 489 yuan ($72), according to one listing on a platform from JD.com reviewed by Reuters.
Competitive Landscape and Market Impact
The treatment, belonging to the class of GLP-1 receptor agonist drugs sold locally by drugmakers such as Novo Nordisk, Eli Lilly, and Innovent Biologics, props up Pfizer's footing in the booming weight-loss drug market.
Sales Performance of Rival Drugs
Sales of Novo's Wegovy on Alibaba’s Tmall e-commerce platform and JD.com were 260 million yuan ($38 million) in 2025, against 416 million yuan ($61 million) for Innovent's Xinermei, investment bank Jefferies said in a note.
Pfizer’s Strategic Partnerships and Approvals
Licensing and Acquisitions
Pfizer licensed the mainland China commercialisation rights for Xianweiying, also known as ecnoglutide, from Sciwind, based in the eastern city of Hangzhou, in February. It has also recently acquired the obesity drug developer Metsera, as well as another experimental GLP-1 drug from another developer.
Regulatory Approvals
Ecnoglutide’s Approval for Diabetes
Ecnoglutide is also approved in China as a treatment for Type 2 diabetes.
(Reporting by Andrew Silver; Editing by Kim Coghill)
Key Takeaways
- •Xianweiying (ecnoglutide) has secured regulatory approval for obesity and diabetes in China, and Pfizer holds exclusive mainland commercialization rights under a deal with Sciwind from Feb 2026 (biospace.com).
- •Listed at 489 yuan per 1.2 ml injector pen on JD.com with deliveries set to begin April 27 (finance.yahoo.com).
- •China’s GLP‑1 obesity market is expanding rapidly, with projections ranging from tens of billions of yuan to over US$11 billion by 2033, amid mounting competition and patent expirations enabling generics (global.chinadaily.com.cn)
References
Frequently Asked Questions about Pfizer GLP-1 weight loss drug available for pre-order in China
1What is Pfizer's new weight management drug available in China?
Pfizer's GLP-1 receptor agonist drug Xianweiying is now available for pre-order in China, targeting the growing weight-loss market.
2How much does Xianweiying cost in China?
A 1.2 ml Xianweiying injector pen costs 489 yuan ($72) with shipping starting April 27, according to listings on JD.com.
3Who are Pfizer's main competitors in the Chinese weight loss drug market?
Pfizer competes with companies like Novo Nordisk, Eli Lilly, and Innovent Biologics, all of whom sell GLP-1 drugs in China.
4What other uses does ecnoglutide (Xianweiying) have besides weight loss?
Ecnoglutide is also approved in China as a treatment for Type 2 diabetes.
5How significant is the market for GLP-1 weight loss drugs in China?
Analysts expect the Chinese GLP-1 weight loss drug market to be worth billions of dollars, driven by sales growth and rising obesity rates.
